Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06565156 · ClinicalTrials.gov registry record · NA
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM
A NA study of Diabetic Foot Ulcer and Diabetic Foot, sponsored by BioStem Technologies.
- Active
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 17
- Study locations
NCT06565156: Active NA study of Diabetic Foot Ulcer and Diabetic Foot, sponsored by BioStem Technologies.
NCT06565156 is a NA study of Diabetic Foot Ulcer and Diabetic Foot that is active but no longer recruiting, run by BioStem Technologies. The registered enrollment target is 72 participants, below the 254-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06565156, a NA study of Diabetic Foot Ulcer and Diabetic Foot, is active but no longer recruiting, sponsored by BioStem Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 17
- Study locations
Study Summary
This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BioREtain® Amniotic Membrane (BR-AM) plus standard of care versus standard of care only in the treatment of diabetic foot ulcers. The trial design will control potential variables that may affect the outcome between the treatment group and the control group by standardizing the requirements for debridement, wound dressings, and offloading. Weekly subject visits will help monitor compliance in wound care and off-loading, as well as to document when wound closure is achieved. The study will also implement the use of an electronic imaging and measurement device using a standardized protocol to ensure the measuring of the wound surface area and volume is accurate, highly reproducible, and minimally variable. There will also be a crossover treatment phase for those patients that were relegated to standard care only. After their 12-week standard of care treatment phase and for only those subjects that did not achieve complete wound closure, will be allowed to crossover for an additional 12 weeks of treatment with the BR-AM product following the protocol and procedures set forth within this document.
Primary Outcome
Percentage of subjects with complete wound closure over the 12-week treatment period, defined as 100% reepithelialization
Conditions Studied
Interventions
- OTHER Standard Care
- OTHER BR-AM
Study Locations (17)
California
- Site 19 - Palmdale
- Site 02 - San Francisco
- Site 01 - Vista
Florida
- Site 27 - Coral Gables
- Site 20 - Deerfield Beach
- Site 28 - DeLand
Texas
- Site 29 - Brownsville
- Site 21 - Burleson
- Site 24 - San Antonio
Arizona
- Site 22 - Mesa
- Site 25 - Tucson
Alabama
- Site 17 - Guntersville
Illinois
- Site 23 - Springfield
Massachusetts
- Site 18 - Boston
Michigan
- Site 26 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT06565156 still lists
NCT06565156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 254-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (72% lower).
The record links to 5 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Standard Care is the first listed.
NCT06565156 lists 17 locations in 10 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT06565156 about?
NCT06565156 is a clinical study titled "Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM". This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BioREtain® Amniotic Membrane (BR-AM) plus standard of care versus standard of care only in the treatment of diabetic foot ulcers. The trial design will control potential variables that may affec...
What is the current status of trial NCT06565156?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2024-10-28. Estimated completion is 2026-06.
What conditions does trial NCT06565156 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Diabetic Foot, Non-infected Diabetic Foot Ulcer, Diabetic Wound, Non-ischemic Diabetic Foot Ulcer.
What interventions are being tested in trial NCT06565156?
The interventions under investigation include: Standard Care (OTHER), BR-AM (OTHER).
Who is sponsoring clinical trial NCT06565156?
This trial is sponsored by BioStem Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06565156 being conducted?
This trial has 17 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06565156's enrollment target sits among peer trials
72 41st of 67 higher than 27 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI